• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Introduction to 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol (CAS No. 955368-98-6)

2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol is a significant compound in the field of pharmaceutical chemistry, characterized by its complex molecular structure and potential therapeutic applications. This compound, identified by the CAS number 955368-98-6, has garnered attention due to its unique chemical properties and its role in the development of novel pharmaceutical agents. The presence of a piperazine ring and an ethanol side chain in its molecular framework suggests potential interactions with biological targets, making it a valuable candidate for further research and development.

The molecular structure of 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol consists of a benzene ring substituted with an amino group at the 4-position and a methyl group at the 2-position. This aromatic system is further linked to a piperazine moiety, which is a six-membered heterocyclic compound containing two nitrogen atoms. The ethanol group attached to the piperazine ring adds another layer of complexity, influencing both the solubility and reactivity of the compound.

Recent advancements in pharmaceutical research have highlighted the importance of piperazine derivatives in drug design. Piperazine-based compounds are known for their ability to interact with various biological targets, including enzymes and receptors, making them effective in treating a wide range of diseases. The specific arrangement of atoms in 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol may contribute to its unique pharmacological properties, potentially making it useful in the treatment of neurological disorders, cardiovascular diseases, and other conditions.

In vitro studies have begun to explore the pharmacokinetic and pharmacodynamic properties of this compound. Initial findings suggest that it may exhibit significant binding affinity to certain receptors, which could be exploited for therapeutic purposes. The amino group at the 4-position of the benzene ring and the piperazine moiety are particularly noteworthy, as they are known to participate in hydrogen bonding and other forms of molecular interaction that are crucial for drug-receptor binding.

The synthesis of 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol involves multi-step organic reactions, requiring precise control over reaction conditions and reagent selection. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to construct the complex molecular framework efficiently. These synthetic strategies not only ensure high yield but also minimize unwanted byproducts, making the process more sustainable and scalable for industrial applications.

One of the most promising areas of research involving 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol is its potential use as an intermediate in the synthesis of more complex pharmaceutical agents. By serving as a building block, this compound can be incorporated into larger molecules designed to target specific disease pathways. For instance, derivatives of this compound may be developed to interact with neurotransmitter receptors, offering new treatments for conditions such as depression, anxiety, and Parkinson's disease.

The ethanol side chain in the molecular structure also plays a critical role in determining the compound's solubility and bioavailability. Compounds with appropriate solubility characteristics are more likely to be effective when administered orally or through other non-invasive routes. Further studies are needed to optimize the solubility profile of 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol through structural modifications or by formulating it with appropriate excipients.

Evaluation of the metabolic stability and toxicity profile is another crucial aspect of drug development. Preliminary data suggest that this compound undergoes moderate metabolic degradation in vivo, with potential for active metabolites that could influence its overall efficacy and safety profile. Detailed toxicological studies are necessary to assess potential side effects and ensure that the compound is safe for human use.

The integration of computational modeling techniques has significantly enhanced our understanding of how 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol interacts with biological targets. Molecular docking simulations can predict binding affinities and identify key interaction points between the compound and its target proteins or receptors. These insights can guide medicinal chemists in designing more effective derivatives with improved pharmacological properties.

Future research directions may include exploring the use of this compound in combination therapies, where it could be paired with other drugs to achieve synergistic effects. Combination therapies are often more effective than single-agent treatments, particularly in treating complex diseases that involve multiple pathological pathways. The unique structural features of 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol make it a promising candidate for such approaches.

In conclusion, 2-4-(4-Amino-2-methylphenyl)-1-piperazinyl-1-ethanol (CAS No. 955368-98-6) represents a significant advancement in pharmaceutical chemistry due to its complex molecular structure and potential therapeutic applications. Its unique combination of functional groups makes it a valuable candidate for further research and development, particularly in treating neurological disorders and other conditions where piperazine-based compounds have shown promise.

• 28005-74-5(Ethanol,2,2'-[(2-methylphenyl)imino]bis-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)